Jiangsu Hengrui Medicine Co., Ltd.
Clinical trials sponsored by Jiangsu Hengrui Medicine Co., Ltd., explained in plain language.
-
Promising prostate cancer combo trial halted early – what it means
Disease control TerminatedThis study tested whether adding the drug SHR3680 to standard hormone therapy could improve outcomes for men with high-risk prostate cancer before they had surgery to remove the prostate. The trial was stopped early, but researchers were looking at whether the combination led to …
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New COPD inhaler shows promise in early trial
Disease control TerminatedThis study tested an experimental inhaled drug called HRG2005 in people with moderate to severe chronic obstructive pulmonary disease (COPD). The goal was to see if it improves lung function compared to an active control. About 200 adults aged 40 and older with a history of COPD …
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Lung cancer combo trial halted early
Disease control TerminatedThis study tested a combination of three drugs—SHR-1210, famitinib, and chemotherapy—in people with advanced non-squamous non-small-cell lung cancer that had not been treated before. The goal was to see if the combination was safe and effective. The trial was stopped early and in…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC